首页> 外文OA文献 >Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing

【2h】

Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing

机译：甲磺酸伊马替尼治疗FIP1L1 / PDGFRA阳性慢性嗜酸性粒细胞白血病停药后复发：最佳剂量的意义

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Klion, Amy D.; Robyn, Jamie; Maric, Irina; Fu, Weiming; Schmid, Laura; Lemery, Steven; Noel, Pierre; Law, Melissa A.; Hartsell, Marilyn; Talar-Williams, Cheryl; Fay, Michael P.; Dunbar, Cynthia E.; Nutman, Thomas B.;
展开▼
作者单位

展开▼
年度 2007
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response [J] . YhimH.-Y., LeeN.-R., SongE.-K., Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis . 2012,第6期

机译：接受甲磺酸伊马替尼一线治疗并获得完全分子应答的慢性骨髓性白血病患者中的甲磺酸伊马替尼停药
2. Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib. [J] . Florian S, Esterbauer H, Binder T, Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis . 2006,第9期

机译：与慢性嗜酸性粒细胞白血病（SM-CEL）相关的全身肥大细胞增多症（SM）：检测FIP1L1 / PDGFRalpha，按WHO标准分类，并对伊马替尼治疗产生反应。
3. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. [J] . Jabbour E, Kantarjian HM, Jones D, Blood: The Journal of the American Society of Hematology . 2009,第10期

机译：甲磺酸伊马替尼剂量递增与标准剂量伊马替尼治疗细胞遗传学失败后的慢性粒细胞白血病患者的持久反应有关。
4. Proteomic Analysis of the Cytoskeleton Regulation in Chronic Myelogenous Leukemia Cells JURL-MK1: Effect of Imatinib Mesylate Treatment [C] . Petr Halada, Katerina Peslova, Dana Grebenova, ASMS Conference on Mass Spectrometry and Allied Topics . 2008

机译：慢性髓性白血病细胞Jull-MK1中细胞骨架调控的蛋白质组学分析：伊马替尼甲磺酸盐处理的影响
5. Influences on physician recommendation for imatinib mesylate in chronic phase chronic myeloid leukemia patients. [D] . Iyer, Shrividya Sethuraman. 2003

机译：对慢性期慢性粒细胞白血病患者甲磺酸伊马替尼的医师推荐的影响。
6. Clinical Trials and Observations: Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing [O] . Amy D. Klion, Jamie Robyn, Irina Maric, -1

机译：临床试验和观察：甲磺酸伊马替尼治疗FIP1L1 / PDGFRA阳性慢性嗜酸性粒细胞白血病停药后复发：最佳剂量的意义
7. Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia [O] . Jovanovic J V, Score J, Waghorn K, 2007

机译：小剂量甲磺酸伊马替尼可导致FIP1L1-PDGFRA阳性慢性嗜酸性粒细胞白血病快速诱导主要分子反应并实现完全分子缓解

Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing

著录项

相似文献

相关主题

期刊订阅